

Paroxetine

Selected References:

- Alwan S, et al. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. *N Engl J Med* 356(26):2684-2692.
- Alwan S, Friedman JM, Chambers C: 2016. Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. *CNS Drugs* 30(6):499-515.
- Andrade S, et al. 2009. Antidepressant use and risk of persistent pulmonary hypertension of the newborn. *Pharmacoepidemiol Drug Saf* 18(3):246-252.
- Bakker MK, et al. 2010. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. *Birth Defects Res A Clin Mol Teratol* 88(2):94-100.
- Berard A, et al. 2016. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: A systematic review and meta-analysis. *Br J Clin Pharmacol*; 81(4):589-604.
- Berard A, et al. 2017. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: An updated analysis of the Quebec Pregnancy Cohort. *BMJ Open*;7:e013372.
- Biffi, A, et al. 2020. Use of antidepressants during pregnancy and neonatal outcomes: An umbrella review of meta-analyses of observational studies. *Journal of Psychiatric Research*, 124:99-108.
- Bonari L, et al. 2004. Perinatal risks of untreated depression during pregnancy. *Can J Psychiatry* 49(11):726-735.
- Chambers C, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 354(6):579-587.
- Costei A, et al. 2002. Perinatal outcome following third trimester exposure to paroxetine. *Arch Pediatr Adolesc Med* 156:1129-1132.
- Creeley, C. E., & Denton, L. K. 2019. Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes. *Brain Sciences*, 9(9)::235
- Den Besten-Bertholee D, et al. 2024. Sertraline, citalopram and paroxetine in lactation: passage into breastmilk and infant exposure. *Front Pharmacol*.15:1414677.
- Desautay P, et al. 2023. Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses. *Paediatr Drugs*. 25(3):247-265.
- De Vries, C., et al. 2020. A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. *Drug Safety*. <https://doi.org/10.1007/s40264-020-01027>
- Diav-Citrin O, et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled observational study. *Br J Clin Pharmacol* 66(5): 695-705.
- Einarson A, et al. 2008. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. *Am J Psychiatry* 165:1-5.
- Einarson A, et al. 2009. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. *J Obstet Gynaecol Can* 31:452-456.
- Fischer Fumeaux, CJ, et al. 2019. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update. *Expert Opinion on Drug Safety*, 18(10):949-963.
- Fitton, CA, et al. 2020. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. *Acta Psychiatrica Scandinavica*, 141(1): 21-33.
- Gabriel M & Sharma V. 2017. Antidepressant discontinuation syndrome. *CMAJ*;189:E747.
- Galbally, M., et al. 2020. Antidepressant exposure in pregnancy and child sensorimotor and visuospatial development. *Journal of Psychiatric Research*;S0022-3956(20)31095-5.

- Gao S, et al. 2018. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. *BMC Med.* 16:205.
- Grigoriadis S et al. 2013. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. *J Clin Psychiatry.* 74(4):e293-308.
- Hansen CH, et al. 2017. The six most widely used selective serotonin reuptake inhibitors decrease androgens and increase estrogens in the H295R cell line. *Toxicol In Vitro.* 41:1-11
- Hendrick V, et al. 2001. Use of sertraline, paroxetine and fluvoxamine by nursing women. *Br J Psychiatry* 179:163-166
- Hernandez-Diaz S. 2007. Risk factors for persistent pulmonary hypertension of the newborn. *Pediatrics* 120 (2):e272-282.
- Jordan S, et al. 2016. Selective serotonin reuptake inhibitor (SSRI) in pregnancy and congenital anomalies: Analysis of linked databases in Wales, Norway and Funen, Denmark. *PLOS One;* 11(12): e0165122.
- Kallen B, et al. 2008. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. *Pharmacoepidemiol Drug Saf* 17(8):801-806.
- Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. *Acta Paediatr.* 104(4):384-91.
- Lebin LG, Novick AM. 2022. Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child. *Curr Psychiatry Rep;* 24, 687-695.
- Leerssen, E. C. M., et al. 2019. Severe transient neonatal long QT syndrome due to maternal paroxetine usage: a case report. *Cardiology in the Young,* 29(10), 1300-1301. <https://doi.org/10.1017/S1047951119001938>
- Levinson-Castiel R, et al. 2006. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. *Arch Pediatr Adolesc Med* 160:173-176.
- Louik C, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. *N Engl J Med* 356(26):2675-2683.
- McDonagh MS, et al. 2014. Antidepressant treatment of depression during pregnancy and the postpartum period. Evidence report/technology assessment No. 216. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2007-10057-I.). Rockville, MD: Agency for Healthcare Research and Quality.
- Mesches, G. A., et al. 2020. A common clinical conundrum: Antidepressant treatment of depression in pregnant women. *Seminars in Perinatology,* 44(3), 151229. <https://doi.org/10.1016/j.semperi.2020.151229>
- Misri S, et al. 2000. Paroxetine levels in postpartum depressed women, breastmilk, and infant serum. *J Clin Psychiatry* 61(11):828-832.
- Molenaar, N. M., et al. 2018. Guidelines on treatment of perinatal depression with antidepressants: An international review. *The Australian and New Zealand Journal of Psychiatry,* 52(4), 320-327.
- Myles N, et al. 2013. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. *Aust N Z J Psychiatry.* 47(11):1002-12.
- Nakhai-Pour HR, et al. 2010. Use of antidepressants during pregnancy and the risk of spontaneous abortion. *CMAJ* 182(10):1031-1037.
- Nulman I, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. *NEJM* 336(4):258-262.
- Nulman I, et al. 2012. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. *Am J Psychiatry.* 2012 169(11):1165-1174.
- Ornoy, A., & Koren, G. 2018. Selective serotonin reuptake inhibitor use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects. *Expert Opinion on Drug Metabolism & Toxicology,* 14(3), 247-259. <https://doi.org/10.1080/17425255.2018.1430139>
- Ornoy A, Koren G. 2014. Selective serotonin reuptake inhibitors in human pregnancy: On the way to resolving the controversy. *Semin Fetal Neonatal Med.* 19(3):188-194.
- Orsolini L, Bellantuono C. 2015. Serotonin reuptake inhibitors and breastfeeding: A systematic review. *Hum Psychopharmacol.* 30:4-20.

- Paxil Prescribing Information, 020936s047lbl.pdf. (n.d.). Retrieved January 7, 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020936s047lbl.pdf
- Pogliani L, Baldelli S, Cattaneo D et al. Selective serotonin reuptake inhibitors passage into human milk of lactating women. *J Matern Fetal Neonatal Med.* 2018;1-11.
- Prady, S. L., et al. 2018. A systematic review of maternal antidepressant use in pregnancy and short- and long-term offspring's outcomes. *Archives of Women's Mental Health*, 21(2), 127-140.
- Raffi, E. R., et al. 2019. Safety of Psychotropic Medications During Pregnancy. *Clinics in Perinatology*, 46(2), 215-234.
- Sanz E, et al. 2005. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. *Lancet* 365:482-487.
- Schoretsanitis G, et al. 2020. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. *Expert Opin Drug Metab Toxicol.*16(5):431-440.
- Stowe Z, et al. 2000. Paroxetine in human breastmilk and nursing infants. *Am J Psychiatry* 157(2):185-189.
- Tanrikut, C., et al. 2010. Adverse effect of paroxetine on sperm. *Fertility and Sterility*, 94(3), 1021-1026.
- Tosounidou, S., & Gordon, C. 2020. Medications in pregnancy and breastfeeding. *Best Practice & Research. Clinical Obstetrics & Gynaecology*, 64, 68-76.
- Trifu, S. C., et al. 2020. Affective disorders: A question of continuing treatment during pregnancy (Review). *Experimental and Therapeutic Medicine*, 20(4), 3474-3482.
- Uguz, F. 2020. Selective serotonin reuptake inhibitors and the risk of congenital anomalies: a systematic review of current meta-analyses. *Expert Opinion on Drug Safety*, 19(12), 1595-1604.
- Uguz F, Arpacı N. 2016. Short-Term Safety of Paroxetine and Sertraline in Breastfed Infants: A Retrospective Cohort Study from a University Hospital. *Breastfeed Med.*11:487-9.
- Uguz F. 2019. Short-term safety of paroxetine plus low-dose mirtazapine during lactation. *Breastfeed Med.* 14(2):131-132.
- Wang S, et al. 2015. Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies. *Journal of the American Heart Association.* 4(5).
- Weissman AM, et al. 2004. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. *Am J Psychiatry* June; 161(6): 1066- 1078.
- Wichman CL, et al. 2009. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. *Mayo Clin Proc* 84(1):23- 27.
- Wurst K, et al. 2010. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. *Birth Defects Res A Clin Mol Teratol* 88(3):159-170
- Yardimci, A., et al. 2019. Effects of long-term paroxetine or bupropion treatment on puberty onset, reproductive and feeding parameters in adolescent male rats. *Andrologia*, 51(6), e13268.
- Zheng L, Yang H, Dallmann A. 2022. Antidepressants and Antipsychotics in Human Pregnancy: Transfer Across the Placenta and Opportunities for Modeling Studies. *J Clin Pharmacol.* 62 Suppl 1:S115-S128.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.

Paroxetine

Selected References:

- Barr DB, et al. 2010. Pesticide concentrations in maternal and umbilical cord sera and their relation to birth outcomes in a population of pregnant women and newborns in New Jersey. *Sci Total Environ*, 408(4):790-795.
- Centers for Disease Control and Prevention. 2022. Prevent Mosquito Bites. Available at URL: <https://www.cdc.gov/zika/prevention/prevent-mosquito-bites.html>.
- Hall JG, et al. 1975. Coarctation of the aorta in male cousins with similar maternal environmental exposure to insect repellent and insecticides. *Pediatrics* 55:425-427.
- Koren G, et al. 2003. DEET-based insect repellents: safety implications for children and pregnant and lactating women. *CMAJ*, 169(3):209-212.
- Kuhlmann RS, et al. 1981. N,N-diethyl-meta-toluamide: embryonic sensitivity. *Teratology*, 23:48a.
- McGready R, et al. 2001. Safety of the insect repellent N,N-diethyl-m-toluamide (DEET) in pregnancy. *Am J Trop Med Hyg*, 65:285-289.
- Özokan G et al. 2024. Comparison of the cytotoxicity and zebrafish embryo toxicity of insect repellent ingredients: p-Methane-3, 8-diol synthesized by green chemistry from *Eucalyptus citriodora* and N, N-diethyl-meta-toluamide. *Drug and Chemical Toxicology*, 47(6): 1193-1294.
- Schaefer C and Peters PW. 1992. Intrauterine diethyltoluamide exposure and fetal outcome. *Reprod Toxicol*, 6:175-176.
- Schoenig GP, et al. 1994. Teratologic evaluations of N,N-diethyl-m-toluamide (DEET) in rats and rabbits. *Fundam Appl Toxicol*, 23:63-69.
- Segal TR, et al. 2017. Urinary concentrations of 3-(diethylcarbamoyl)benzoic acid (DCBA), a major metabolite of N,N-diethyl-m-toluamide (DEET) and semen parameters among men attending a fertility center. *Hum Reprod*, 32(12): 2532-2539.
- Selim S, et al. 1995. Absorption and metabolism of DEET following dermal application to human volunteers. *Fundam Appl Toxicol*, 25:95-100.
- Snodgrass RL, et al. 1982. Dermal penetration and potential for placental transfer of the insect repellent, N,N-diethyl-m-toluamide. *Am Ind Hyg Assoc J*, 43:747-753.
- Sudakin DL, Trevathan WR. 2003. DEET: a review and update of safety and risk in the general population. *J Toxicol Clin Toxicol*. 41(6):831-9.
- United States Environmental Protection Agency (EPA). 2022. DEET. Available at URL: <https://www.epa.gov/insect-repellents/deet>.
- Wickerham EL, et al. 2012. Reduced birth weight in relation to pesticide mixtures detected in cord blood of full-term infants. *Environmental International*, 47:80-85.
- Wright DM, et al. 1992. Reproductive and developmental toxicity of N,N-diethyl-m-toluamide in rats. *Fundam Appl Toxicol*, 19:33-42.
- Wylie BJ, et al. 2016. Insect repellents during pregnancy in the era of the Zika virus. *Obstet Gynecol*,

128(5):1111-1115.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.

Paroxetine

Selected References:

- American College of Obstetricians and Gynecologists. 2013. ACOG committee opinion no. 558: Integrating immunizations into practice. *Obstet Gynecol* 121(4):897-903.
- Angelo MG, et al. 2014. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. *Pharmacoepidemiol Drug Saf*. 23(5):466-79.
- Baril L, et al. 2015. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. *Vaccine* 33(48):6884-91.
- Bukowski AT, et al. 2020. Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy. *Vaccine*. 18;38(37):5933-5939.
- Centers for Disease Control and Prevention. 2025. Human Papillomavirus (HPV) Vaccine Safety. Available at <https://www.cdc.gov/vaccine-safety/vaccines/hpv.html>
- Chen W, et al. 2019. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. *Vaccine* 37(6):889-97.
- Dousti R, Allahqoli L, Ayar Kocaturk A, Hakimi S. 2023. Can human papillomavirus vaccination during pregnancy result in miscarriage and stillbirth? A meta-analysis and systematic review. *Eur J Midwifery*. 2023;7:9.
- Faber MT, et al 2019. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy. *Vaccine* 37(2):265-271.
- Garland SM, et al. 2009. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type

6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. *Obstet Gynecol* 114(6):1179-1188.

- Garolla A et. Al. 2013. Sperm viral infection and male infertility: focus on HBV, HCV, HIV, HPV, HSV, HCMV, and AAV. *J Reprod Immunol* 100(1):20-9.
- Goss MA, et al. 2015. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. *Vaccine* 33(29): 3422-3428.
- Forbes N, Montroy J, Salvadori MI, Dubey V. 2024. Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated guidance on human papillomavirus (HPV) vaccines. *Can Commun Dis Rep*. 50(12):419-425.
- Kharbanda EO, et al. 2018. Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. *Obstet Gynecol* 132:34-44.
- Kharbanda EO, et al. 2021. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. *JAMA Netw Open* 4(4): e214340.
- Landazabal CS, et al. 2019. Safety of 9- valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017. *Vaccine* 37:1229-1234.
- Lawton B, et al. 2018. Association of prior HPV vaccinations with reduced preterm birth: a population based study. *Vaccine* 36: 134-140.
- Lipkind HS, et al. 2017. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. *Obstet Gynecol*; 130(3):599-608.
- Mammas IN, et al. 2011. Can 'high-risk' human papillomaviruses (HPVs) be detected in human breast milk? *Acta Paediatr* 100(5):705-7.
- Markowitz LE, et al. 2007. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 56 (RR-2):1-24.
- Matys K, et al. 2012. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. *Clin Vaccine Immunol* Jun; 19(6):881-5.
- McDonnold M, et al. 2014. High risk human papillomavirus at entry to prenatal care and risk of preeclampsia. *Am J Obstet Gynecol* 210(2):138.e1-5.
- Moreira ED, E et al. 2016. Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. *Pediatrics*. 138(2):e20154387.
- Muscianisi F, Foresta C, Garolla A. Role of HPV vaccination for prevention of male infertility. *Minerva Endocrinol* (Torino). 2022 Mar;47(1):70-76.
- Panagiotou OA, et al. 2015. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. *BMJ* 7; 351:h4358.
- Segal L, et al. 2011. Evaluation of the intramuscular administration of Cervarix vaccine on fertility, pre- and post-natal development in rats. *Reprod Toxicol* 31(1):111-20.
- Scheller NM, et al. 2017. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. *N Engl J Med* 376:1223-1233.
- Wacholder S, et al. 2010. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized clinical trials. *BMJ* 340:C712.
- Wang A, et al. 2020. Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-analysis. *Hum Vaccin Immunother*. 3;16(3):581-589.
- Wise LD, et al. 2008. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. *Birth Defects Res (B)* 83:561-572.
- Yan X, Li H, Song B, et al. 2023. Association of periconceptional or pregnancy exposure of HPV vaccination and adverse pregnancy outcomes: A systematic review and meta-analysis with trial sequential analysis. *Front Pharmacol*. 2023;14:1181919
- Zhang J, Lian Z, Xue X, et al. 2024. Does HPV vaccination during periconceptional or gestational period increase the risk of adverse pregnancy outcomes?-An updated systematic review and meta-analysis based on timing of vaccination. *Acta Obstet Gynecol Scand*. 103(10):1943-1954.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.

Paroxetine

Selected References:

- Adane AA, et al. 2016. Diabetes in pregnancy and childhood cognitive development: a systematic review. *Pediatrics*, 137(5):e20154234.
- American Diabetes Association. 2024. Management of diabetes in pregnancy: Standards of care in diabetes—2024. *Diabetes Care*. 47(Supplement_1):S282-S294.
- Bhattacharyya A, et al. 2001. Insulin lispro and regular insulin in pregnancy. *QJM*. 94(5):255-260.
- Bytoft B, et al. 2016. Long-term cognitive implications of intrauterine hyperglycemia in adolescent offspring of women with type 1 diabetes (the EPICOM Study). *Diabetes Care*, 39:1356-1363.
- Chehab RF, et al. 2022. Glycemic control trajectories and risk of perinatal complications among individuals with gestational diabetes. *JAMA Netw Open*, 5(9):e2233955.
- Chen K-R, et al. 2023. Childhood neurodevelopmental disorders and maternal diabetes: A population-based cohort study. *Dev Med Child Neurol*. 65:933-941.
- Coetzee EJ and Levitt NS. 2000. Maternal diabetes and neonatal outcome. *Seminars in Neonatology*. 5(3):221-229.
- Feleke BE, et al. 2022. Maternal and newborn effects of gestational diabetes mellitus: A prospective cohort study. *Prim Care Diabetes*, 16(1):89-95.
- Kinnunen J, et al. 2023 Gestational diabetes is associated with the risk of offspring's congenital anomalies: a register-based cohort study. *BMC Pregnancy Childbirth*. 23(1):708.
- Landon MB. 2000. Obstetric management of pregnancies complicated by diabetes mellitus. *Clinical Obstetrics and Gynecology*, 43(1):65-74.
- Langer O, et al. 2000. A comparison of glyburide and insulin in women with gestational diabetes mellitus. *New*

England Journal of Medicine, 343(16):1134-1138.

- Leth-Møller M, et al. 2024. Effect of gestational diabetes on fetal growth rate and later overweight in the offspring, Journal of Clinical Endocrinology & Metabolism. dgae428.
- Meek CL. 2023. An unwelcome inheritance: childhood obesity after diabetes in pregnancy. Diabetologia. 66:1961-1970.
- Nagasawa M, et al. 2024. Maternal diabetes and risk of offspring congenital heart diseases: the Japan Environment and Children's Study. Environ Health Prev Med. 29:23.
- National Institute of Child Health and Human Development. 2011. Managing Gestational Diabetes: A Patient's Guide to a Healthy Pregnancy. Available at: <https://www.nichd.nih.gov/publications/product/211>. [Accessed February 2023]
- Ornoy A. 2005. Growth and neurodevelopmental outcome of children born to mothers with pregestational and gestational diabetes. Pediatr Endocrinol Rev, 3(2):104-113.
- Papazoglou AS, et al. 2022. Maternal diabetes mellitus and its impact on the risk of delivering a child with congenital heart disease: a systematic review and meta-analysis. J Matern Fetal Neonatal Med, 35(25):7685-7694.
- Pectasides M and Kalva S. 2011. Diabetes revealed: multisystem danger. American Journal of Roentgenology, 196(2): 274-286.
- Preda A, et al. 2021. Analysis of maternal and neonatal complications in a group of patients with gestational diabetes mellitus. Medicina, 57(11):1170.
- Rizzo TA, et al. 1995. Prenatal and perinatal influences on long-term psychomotor development in offspring of diabetic mothers. Am J Obstet Gynecol, 173(6):1753-1758.
- Rosenn BM and Miodovnik M. 2000. Medical complications of diabetes mellitus in pregnancy. Clinical Obstetrics and Gynecology, 43(1):17-31.
- Santos JDC, et al. 2023. Diabetes among women with preterm births: outcomes of a Brazilian multicenter study. Einstein (Sao Paulo). 21:eAO0515.
- Sells CJ, et al. 1994. Long-term developmental follow-up of infants of diabetic mothers. J Pediatr, 125(1):S9-17.
- Serlin D and Last R. 2009. Diagnosis and management of gestational diabetes mellitus. American Family Physician, 80(1): 57-62.
- Sweeting A, et al. 2024. Relationship between early-pregnancy glycemia and adverse outcomes: findings from the TOBOGM study. Diabetes Care. 47(12): 2085-2092.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.

Paroxetine

Selected References:

- Adam DN, et al. 2023. Expert consensus on the systemic treatment of atopic dermatitis in special populations. *J Eur Acad Dermatol Venereol*. 37(6):1135-1148.
- Balakirski G, et al. 2022. Atopic dermatitis and pregnancy. *J Allergy Clin Immunol*. 149(4):1185-1194.
- Hamann CR, et al. 2019. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. *J Eur Acad Dermatol Venereol*. Mar;33(3):577-587.
- Horev, A., Shalom, G., Weintraub, A. Y., Freud, T., & Cohen, A. D. 2022. Atopic Dermatitis and Infertility: A Nationwide Retrospective Cohort Study. *Dermatology (Basel, Switzerland)*, 238(2), 313-319.
- Kim J, et al. 2019. Pathophysiology of atopic dermatitis: Clinical implications. *Allergy Asthma Proc*. 40(2):84-92.
- Koutroulis I, et al. 2011. Atopic dermatitis in pregnancy: current status and challenges. *Obstet Gynecol Surv*. 66(10):654-663.
- Munera-Campos M, et al. 2024. Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives. *Am J Clin Dermatol*. 25(1):55-66.
- Napolitano M, et al. 2021. New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding. *Dermatol Ther*. 34(1):e14475.
- Pfaller B, et al. 2020. Biologicals in atopic disease in pregnancy: an EAACI position paper. *Allergy*. 76(1):71-89.
- Ramos CL, et al. (2023). Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation. *Immunol Allergy Clin North Am*. 43(1):187-197.
- Schuler CF, et al. 2023. Novel insights into atopic dermatitis. *Allergy Clin Immunol*. 151(5):1145-1154.
- Silverberg J. I. 2018. Associations between atopic dermatitis and other disorders. *F1000Research*, 7, 303.
- Sroka-Tomaszewska J, et al. 2021. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. *Int J Mol Sci*. 22(8):4130.
- Torres T, et al. 2019. Update on Atopic Dermatitis. *Acta Med Port*. 32(9):606-613.
- Vaughan Jones SA, et al. 1999. A prospective study of 200 women with dermatoses of pregnancy correlating the clinical findings with hormonal and immunopathological profiles. *Br J Dermatol*. 141:71-81.
- Vestergaard C, et al. 2019. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. *J Eur Acad Dermatol Venereol*. 33(9):1644-1659
- Wollenberg A. et al. 2022. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. *J Eur Acad Dermatol Venereol*. 2022 Nov;36(11):1904-1926.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.